Clinical Trial Update: A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial evaluated abemaciclib (LY2835219) in postmenopausal women with hormone receptor-positive, HER2-negative breast cancer; results were …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Abemaciclib (abemaciclib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Breast Cancer, Hormone Receptor Positive Tumor | Phase 2 | Status: COMPLETED | Results posted: 2018-01-30